Maura Gillison
Expertise in
7
conditions

Dr. Maura Gillison

Oncology
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 
Expertise in
7
conditions
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 

Overview

Maura Gillison is an Oncologist in Cary, North Carolina. Dr. Gillison is highly rated in 7 conditions, according to our data. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Neuroendocrine Tumor, Anal Cancer, Tongue Cancer, and Gastrostomy.

Her clinical research consists of co-authoring 185 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in TX

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

UT MD Anderson Cancer Center
210 Ashville Ave # 408, Cary, NC 27518

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Drug, Procedure, Radiation, Other
Study Drug: Peposertib
Study Phase: Phase 1
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2026
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
Phase 2 Study (With Safety Lead in) of the Safety, Tolerability and Efficacy of Anti-CTLA4 (Ipilimumab) and Anti-PD-1 (Nivolumab) in Combination With Radiation Therapy to 50-66 Gy in Low-Intermediate Volume, Local-Regionally Advanced HPV-Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Phase 2 Study (With Safety Lead in) of the Safety, Tolerability and Efficacy of Anti-CTLA4 (Ipilimumab) and Anti-PD-1 (Nivolumab) in Combination With Radiation Therapy to 50-66 Gy in Low-Intermediate Volume, Local-Regionally Advanced HPV-Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Study Of Induction Chemotherapy With Cisplatin/Carboplatin, And Docetaxel With Or Without Erlotinib In Patients With Head And Neck Squamous Cell Carcinomas Amenable For Surgical Resection
Randomized, Placebo-Controlled, Phase 2 Study Of Induction Chemotherapy With Cisplatin/Carboplatin, And Docetaxel With Or Without Erlotinib In Patients With Head And Neck Squamous Cell Carcinomas Amenable For Surgical Resection
Enrollment Status: Completed
Publish Date: November 26, 2025
Intervention Type: Behavioral, Drug, Other
Study Drugs: Docetaxel, Erlotinib
Study Phase: Phase 2
A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase II Study of OSI-774 in Combination With Cisplatin and Docetaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer
A Phase II Study of OSI-774 in Combination With Cisplatin and Docetaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 26, 2025
Intervention Type: Drug
Study Phase: Phase 2
Phase II Investigation of Adjuvant Combined Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma
Phase II Investigation of Adjuvant Combined Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2024
Intervention Type: Radiation, Procedure, Drug
Study Drugs: Pembrolizumab, Cisplatin
Study Phase: Phase 2
A Randomized, Placebo-Controlled, Phase 2 Study of Docetaxel and Cisplatin/Carboplatin With or Without Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
A Randomized, Placebo-Controlled, Phase 2 Study of Docetaxel and Cisplatin/Carboplatin With or Without Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Enrollment Status: Completed
Publish Date: July 16, 2024
Intervention Type: Other, Drug
Study Phase: Phase 2
TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation
TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Lapatinib
Study Phase: Phase 2
View 9 Less Clinical Trials

185 Total Publications

Treatment Interruption and Outcomes in Head and Neck Cancer: A Secondary Analysis of 3 Randomized Clinical Trials.
Treatment Interruption and Outcomes in Head and Neck Cancer: A Secondary Analysis of 3 Randomized Clinical Trials.
Journal: JAMA otolaryngology-- head & neck surgery
Published: December 04, 2025
Similar Doctors
Expertise in
26
conditions
Dr. Alessandra Ferrajoli
Oncology
Expertise in
26
conditions
Dr. Alessandra Ferrajoli
Oncology

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (1050.4 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances

Alessandra Ferrajoli is an Oncologist in Cary, North Carolina. Dr. Ferrajoli is highly rated in 26 conditions, according to our data. Her top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
29
conditions
Dr. Anthony Conley
Oncology
Expertise in
29
conditions
Dr. Anthony Conley
Oncology

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (1050.4 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anthony Conley is an Oncologist in Cary, North Carolina. Dr. Conley is highly rated in 29 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Chondrosarcoma, Alveolar Soft Part Sarcoma, Liposarcoma, and Salpingo-Oophorectomy.

Expertise in
19
conditions
Dr. Michelle Fanale
Oncology
Expertise in
19
conditions
Dr. Michelle Fanale
Oncology

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (1050.4 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances

Michelle Fanale is an Oncologist in Cary, North Carolina. Dr. Fanale is highly rated in 19 conditions, according to our data. Her top areas of expertise are Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Bone Marrow Aspiration, and Tissue Biopsy.

Frequently Asked Questions about Dr. Maura Gillison

How do I make an appointment with Dr. Maura Gillison?

You can book an appointment with Dr. Maura Gillison by calling their office at 713-792-6161. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Maura Gillison a top-rated expert for Head and Neck Squamous Cell Carcinoma (HNSCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Maura Gillison is classified as an Elite expert for Head and Neck Squamous Cell Carcinoma (HNSCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Maura Gillison specialize in?

While Dr. Maura Gillison is a Oncology, they have specific expertise in Head and Neck Squamous Cell Carcinoma (HNSCC), Neuroendocrine Tumor, and Anal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Maura Gillison participate in research or clinical trials?

Yes. Dr. Maura Gillison has published 185 articles and abstracts on conditions like Head and Neck Squamous Cell Carcinoma (HNSCC). You can view a list of Dr. Maura Gillison's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Maura Gillison accept my insurance?

Dr. Maura Gillison accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 713-792-6161 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gillison's expertise for a condition
ConditionClose
    View All 22 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile